https://pittplusme.org/study/phio
Phio Study
STUDY BASICS
Do you have squamous cell skin cancer, melanoma, or Merkel cell skin cancer? You may be eligible for a research study to test the safety and tolerability of an intratumorally administered product that may help the body destroy the tumor. Compensation is provided.
STUDY PURPOSE
This study is investigating if PH-762 can help your immune system in its fight against cancer. More specifically, they are studying if PH-762 injections in a tumor lesion can help. The study drug, PH-762, is experimental, which means it has not been fully tested for its safety, tolerability, and biological activity. PH-762 has been used in another clinical study in humans with advanced melanoma. The FDA has not approved it for sale or use.
COULD THIS STUDY BE RIGHT FOR YOU?
- Be at least 18 years of age
- Have had a biopsy confirming the diagnosis of squamous cell skin cancer, melanoma, or Merkel Cell skin cancer
- Have at least one tumor accessible for intratumoral injection that measures 1 to 3 centimeters.
- Additional study criteria will be described by the study staff
WHAT PARTICIPANTS CAN EXPECT
- Study visits over a 4-5 month period
- 4 intratumoral injection visits
- Study procedures at no cost to you including:
- Physical exams, ECGs and safety labs
- Tumor excision
IRB: SSU00240483
- Phio Pharmaceuticals Corp. - PHIO-762-2301, Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma (Pro00073270)
MEET THE RESEARCHER
Joe K. Tung
Joe K. Tung, MD, MBA received his undergraduate degree in Molecular Biophysics and Biochemistry at Yale University and his medical degree at Harvard Medical School. He concurrently obtained his Master of Business Administration from Harvard Business School, graduating in the top 5% as a Baker Scholar. Dr. Tung went on to complete his internal medicine intern year at the Brigham and Women's Hospital and his dermatology residency at the University of Pittsburgh Medical Center.
Dr. Tung won a gold medal representing the United States at the 43rd International Chemistry Olympiad. His basic science and clinical research work have resulted in multiple peer-reviewed articles, reviews, textbook chapters, clinical decision support tools, and presentations at national and international meetings. He serves as a reviewer for research journals, as a consultant for pharmaceutical and biotechnology companies, as a principal investigator for global industry-sponsored clinical trials, and as an advisor for multiple healthcare start-ups. In his spare time, Dr. Tung enjoys traveling, playing golf, rock climbing, visiting museums, and attending live sporting events.